Adalimumab is a monoclonal anti-rheumatic drug that modifies the disease and works by activating tumor necrosis factors-alpha (TNFa). Like other TNF inhibitors, it is an immunosuppressive medication, used to treat autoimmune diseases such as juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult crohn's disease, pediatric crohn's disease, ulcerative colitis,uveitis, plaque psoriasis, and hidradenitis suppurativa. Adalimumab has been shown to reduce the signs and symptoms of moderate to severe rheumatoid arthritis as well in adults. It has the same effectiveness as methotrexate and, in combination with it, it nearly doubles the response rate of methotrexate alone. Since 2002, Adalimumab has been approved for medical use in the United States. It is also listed on the (WHO) World Health Organization's List of Essential Medicines. It is also available as a biosimilar medicine. It was the 178th most prescribed medication in the United States in 2018, with over 3 million prescriptions. Adalimumab can cause upper respiratory tract infections, headaches, pain at injection sites, rash and pain. Although it is not recommended to use Adalimumab during pregnancy, some sources suggest that breastfeeding may be possible. Side effects include anaphylaxis and reactivation hepatitis B. There is strong evidence to suggest that Adalimumab can increase your risk of developing serious infections such as tuberculosis. It has also been reported that it may increase your risk of developing other cancers. This association could be due to an increased chance of malignancies in the conditions being treated and not adalimumab.

A Humira subcutaneous kit (40 mg/0.8 mL) is around $6,240 for a supply of 2 kits, two subcutaneous kits typically contain only a month's supply of Adalimumab. It is sold under the brand name Humira, among others such as: Hulio, Hyrimoz, Abrilada, Amjevita, Cyltezo, Hadlima, etc.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Adalimumab offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for Adalimumab manufacturers and Adalimumab suppliers that you are looking for. These also enable you to check the dossier status of Adalimumab, and the GMP approvals of the different variants of Adalimumab. Also, each manufacturer or supplier product description contains essential information about Adalimumab including clinical data, stability zones, countries where Adalimumab is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over Adalimumab offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and ordering processes. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers or suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that Adalimumab manufacturers list has, we qualify their companies before they are boarded on the platform. This allows us to screen Adalimumab manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.